BACKGROUND: Black men in the United States have substantially higher prostate cancer incidence rates than the general population. The extent to which this incidence disparity is because prostate cancer is more prevalent, more aggressive, and/or more frequently diagnosed in black men is unknown. METHODS: The authors estimated 3 independently developed models of prostate cancer natural history in black men and in the general population using an updated reconstruction of prostate-specific antigen screening, based on the National Health Interview Survey in 2005 and on prostate cancer incidence data from the Surveillance, Epidemiology, and End Results program during 1975 through 2000. By using the estimated models, the natural history of prostate cancer was compared between black men and the general population. RESULTS: The models projected that from 30% to 43% (range across models) of black men develop preclinical prostate cancer by age 85 years, a risk that is (relatively) 28% to 56% higher than that in the general population. Among men who had preclinical disease onset, black men had a similar risk of diagnosis (range, 35%-49%) compared with the general population (32%-44%), but their risk of progression to metastatic disease by the time of diagnosis was from 44% to 75% higher than that in the general population. CONCLUSIONS: Prostate cancer incidence patterns implicate higher incidence of preclinical disease and higher risk of metastatic progression among black men. The findings suggest screening black men earlier than white men and support further research into the benefit-harm tradeoffs of more aggressive screening policies for black men. Cancer 2017;123:2312-2319.
BACKGROUND: Black men in the United States have substantially higher prostate cancer incidence rates than the general population. The extent to which this incidence disparity is because prostate cancer is more prevalent, more aggressive, and/or more frequently diagnosed in black men is unknown. METHODS: The authors estimated 3 independently developed models of prostate cancer natural history in black men and in the general population using an updated reconstruction of prostate-specific antigen screening, based on the National Health Interview Survey in 2005 and on prostate cancer incidence data from the Surveillance, Epidemiology, and End Results program during 1975 through 2000. By using the estimated models, the natural history of prostate cancer was compared between black men and the general population. RESULTS: The models projected that from 30% to 43% (range across models) of black men develop preclinical prostate cancer by age 85 years, a risk that is (relatively) 28% to 56% higher than that in the general population. Among men who had preclinical disease onset, black men had a similar risk of diagnosis (range, 35%-49%) compared with the general population (32%-44%), but their risk of progression to metastatic disease by the time of diagnosis was from 44% to 75% higher than that in the general population. CONCLUSIONS:Prostate cancer incidence patterns implicate higher incidence of preclinical disease and higher risk of metastatic progression among black men. The findings suggest screening black men earlier than white men and support further research into the benefit-harm tradeoffs of more aggressive screening policies for black men. Cancer 2017;123:2312-2319.
Authors: Vickie L Shavers; Martin L Brown; Arnold L Potosky; Carrie N Klabunde; W W Davis; Judd W Moul; Angela Fahey Journal: J Gen Intern Med Date: 2004-02 Impact factor: 5.128
Authors: Daniel A Barocas; Darryl T Gray; Jay H Fowke; Nathaniel D Mercaldo; Jeffrey D Blume; Sam S Chang; Michael S Cookson; Joseph A Smith; David F Penson Journal: J Urol Date: 2012-08-16 Impact factor: 7.450
Authors: Ruth Etzioni; Alex Tsodikov; Angela Mariotto; Aniko Szabo; Seth Falcon; Jake Wegelin; Dante DiTommaso; Kent Karnofski; Roman Gulati; David F Penson; Eric Feuer Journal: Cancer Causes Control Date: 2007-11-20 Impact factor: 2.506
Authors: Farzana A Faisal; Debasish Sundi; Jeffrey J Tosoian; Voleak Choeurng; Mohammed Alshalalfa; Ashley E Ross; Eric Klein; Robert Den; Adam Dicker; Nicholas Erho; Elai Davicioni; Tamara L Lotan; Edward M Schaeffer Journal: Eur Urol Date: 2015-10-09 Impact factor: 20.096
Authors: Anqi Wang; Mariana Lazo; H Ballentine Carter; John D Groopman; William G Nelson; Elizabeth A Platz Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-06-03 Impact factor: 4.254
Authors: Arsheed A Ganaie; Firdous H Beigh; Matteo Astone; Marina G Ferrari; Raihana Maqbool; Syed Umbreen; Aijaz S Parray; Hifzur R Siddique; Tabish Hussain; Paari Murugan; Colm Morrissey; Shahriar Koochekpour; Yibin Deng; Badrinath R Konety; Luke H Hoeppner; Mohammad Saleem Journal: Clin Cancer Res Date: 2018-08-07 Impact factor: 12.531
Authors: Nathaniel Hendrix; Roman Gulati; Boshen Jiao; A Karim Kader; Stephen T Ryan; Ruth Etzioni Journal: Am J Epidemiol Date: 2021-10-01 Impact factor: 4.897